Product
Perindopril/Indapamide/Amlodipine
1 clinical trial
1 indication
Indication
bioequivalenceClinical trial
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril Erbumine/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg Tablets (Pharmtechnology LLC, Republic of Belarus) and Triplixam® 10 mg/2.5 mg/10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting ConditionsStatus: Recruiting, Estimated PCD: 2023-08-17